121 related articles for article (PubMed ID: 9580265)
1. [Histomorphometry study of the effect of an inhibitor of 5-alpha reductase on the coating of human prostate explants in tissue culture].
López Muñoz A; Larrán Lopez J; Salido Peracaula M; Aparicio Patino J; Vilches Troya J
Actas Urol Esp; 1998 Jan; 22(1):11-6. PubMed ID: 9580265
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of the effect of a 5-alpha-reductase inhibitor on cultured explants of human prostate].
López Munñoz A; Lárran López J; Aparicio Patino J; Muñoz de la Pascua MC; Salido Peracaula M; de Palacio Rubio ML; Romero Gutiĕrrez L; Rodríguez Vallejoo JM
Actas Urol Esp; 1996 Apr; 20(4):316-22; discussion 323. PubMed ID: 8801791
[TBL] [Abstract][Full Text] [Related]
3. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
4. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate.
Yamashita A; Hayashi N; Sugimura Y; Cunha GR; Kawamura J
Prostate; 1996 Jul; 29(1):1-14. PubMed ID: 8685049
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
6. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
Iguer-Ouada M; Verstegen JP
J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
[TBL] [Abstract][Full Text] [Related]
7. Effects of a 5 alpha-reductase inhibitor, finasteride, on the developing prostate and testis of a marsupial.
Ryhorchuk AR; Shaw G; Butler CM; Renfree MB
J Androl; 1997; 18(2):123-30. PubMed ID: 9154506
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase inhibitors.
Rittmaster RS
J Androl; 1997; 18(6):582-7. PubMed ID: 9432130
[No Abstract] [Full Text] [Related]
9. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
10. Effects of finasteride on vascular endothelial growth factor.
Häggström S; Tørring N; Møller K; Jensen E; Lund L; Nielsen JE; Bergh A; Damber JE
Scand J Urol Nephrol; 2002; 36(3):182-7. PubMed ID: 12201932
[TBL] [Abstract][Full Text] [Related]
11. [Is tumour grade applicable to finasteride-treated prostate cancer?].
Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
13. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
14. Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate.
Cabeza M; Bratoeff E; Heuze I; Ramírez E; Sánchez M; Flores E
Proc West Pharmacol Soc; 2003; 46():153-5. PubMed ID: 14699915
[No Abstract] [Full Text] [Related]
15. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the regulation of prostatic oxytocin by gonadal steroids in the rat.
Jenkin L; Nicholson HD
J Androl; 1999; 20(1):80-7. PubMed ID: 10100477
[TBL] [Abstract][Full Text] [Related]
19. Prevention of prostate cancer with finasteride.
Rubin MA; Kantoff PW
N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14561801
[No Abstract] [Full Text] [Related]
20. [5-alpha-reductase inhibitors].
De Jaegher K; Kozyreff P; Claes H
Acta Urol Belg; 1994 Dec; 62(4):23-31. PubMed ID: 7540795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
